Cyprus a benchmark for beta-thalassaemia, myelodysplastic syndromes management

Contemporary challenges, the value of institutional collaboration and new therapeutic options in the management of beta-thalassaemia and myelodysplastic syndromes were the focus of a press conference held in Cyprus by the biopharmaceutical company Bristol Myers Squibb on…

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Cyprus Mail.